NextCure, Inc. (NASDAQ:NXTC) is seeing a significant decrease in short interest

NextCure, Inc. (NASDAQ:NXTC – Get Free Report ) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totaling 65,800 shares, a decrease of 15.4% from its August 31st total of 77,800 shares. About 0.3% of the company’s shares are short-sold. Based on an average trading volume of 45,000 shares, the short interest rate is currently 1.5 days.

Institutional investors are stepping in on NextCure

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of NextCure by 9.3% in the first quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock valued at $2,202,000 after purchasing an additional 83,700 shares in the last quarter. Cable Car Capital LLC purchased a new position in shares of NextCure in the fourth quarter valued at $702,000. Logos Global Management LP boosted its holdings in NextCure by 29.9% in the second quarter. Logos Global Management LP now owns 2,500,000 shares of the company’s stock valued at $3,975,000 after purchasing an additional 575,000 shares during the last quarter. Affinity Asset Advisors LLC boosted its stake in NextCure by 24.2% in the second quarter. Affinity Asset Advisors LLC now owns 1,687,955 shares of the company’s stock valued at $2,684,000 after buying an additional 328,918 shares during the last quarter. Finally, Armistice Capital LLC acquired a new stake in NextCure in the second quarter worth approximately $57,000. Institutional investors and hedge funds own 42.65% of the company’s shares.

Analysts on Wall Street are forecasting an increase

A number of brokerages have issued reports on NXTC. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of NextCure in a research report on Friday, May 31st. Needham & Company LLC reissued a “buy” rating and set a $4.00 target price on shares of NextCure in a research note on Friday, August 2nd.

See our latest review on NextCure

NextCure trading down 2.1%

NXTC traded down $0.03 during trading hours on Friday, reaching $1.38. 10,027 shares of the company’s stock were exchanged, compared to its average volume of 137,928. The firm has a market cap of $38.60 million, a P/E ratio of -0.61 and a beta of 0.79. NextCure has a 12-month low of $0.98 and a 12-month high of $2.57. The firm has a 50-day moving average of $1.51 and a 200-day moving average of $1.59.

NextCure (NASDAQ:NXTC – Get Your Free Report ) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.19). As a group, research analysts expect that NextCure will post -1.79 EPS for the current fiscal year.

NextCure Company Profile

(Get a free report)

NextCure, Inc, a clinical-stage biopharmaceutical company, is engaged in the discovery and development of new immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block LAIR-1-mediated immune suppression; NC762, a monoclonal antibody that specifically binds to B7-H4, a protein expressed on several tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemia stem cells while sparing normal blood cells, including hematopoietic stem cells.

See Also

Get news and reviews for NextCure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NextCure and related companies with MarketBeat.com’s FREE daily email newsletter.